摘要
尽管非小细胞肺癌(non-small cell lung cancer,NSCLC)治疗后向小细胞肺癌(small cell lung cancer,SCLC)的转化在肺腺癌患者中较为多见,并被认为可能是表皮生长因子受体酪氨酸激酶抑制剂(epidermal growth factor receptor tyrosine kinase inhibitors,EGFR-TKI)耐药的机制之一,也可能是耐药的伴随现象;但SCLC的转化在不同的病理类型中均有报道,除了EGFR-TKI治疗,目前的肿瘤治疗手段如化疗、放疗等也可导致这种转化的发生。转化的发生给临床诊疗带了很大的困惑,虽然个案报道层出不穷,但大样本回顾性研究分析却鲜有报道。本文就目前现有的NSCLC治疗后向SCLC转化的临床回顾性研究分析进行归纳总结,为开展更深入的临床研究提供线索及理论依据。
Although the transformation from non-small cell lung cancer(NSCLC) into small cell lung cancer(SCLC) is relatively more common in patients with lung adenocarcinoma, which is suspected as one of the mechanisms of epidermal growth factor receptor tyrosine kinase inhibitors(EGFR-TKI) resistance, or could be the accompanying phenomenon of drug resistance. However, the occurrence of the transformation from NSCLC to SCLC was also reported in patients with NSCLC of different pathological types. In addition to EGFR-TKI treatment, current therapeutic regimens of cancer such as chemotherapy, radiotherapy etc. can also result in this transformation. The transformation has brought about a lot of confusion to the process of clinical diagnosis and treatment. In spite of many case reports about the transformation, there were merely several large-scale retrospective clinical analyses. This review summarized several relatively large samples retrospective studies about the transformation;therefore, we could provide clues and theoretical basis for more in-depth clinical researches.
作者
朱魁魁
张盛
伍钢
孟睿
Zhu Kuikui;Zhang Sheng;Wu Gang;Meng Rui(Cancer Center,Union Hospital Affiliated to Tongji Medical College of Huazhong University of Science and Technology,Wuhan 430022,Hubei,China)
出处
《肿瘤预防与治疗》
2020年第2期179-183,共5页
Journal of Cancer Control And Treatment
基金
中国临床肿瘤学会基金项目(编号:Y-2019 Genecast-061,Y-sy2018-018)~~
关键词
非小细胞肺癌
小细胞肺癌
治疗
转化
Non-small cell lung cancer
Small cell lung cancer
Therapy
Transformation
